BEIJING, China, April 21, 2017 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the"Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release first quarter of 2017 financial results on Wednesday, May
The Company's management will hold a conference call at 7:30 a.m. ET on Thursday, May 4, 2017, which is 7:30 p.m., Beijing Time on May 4, 2017, to discuss first quarter of 2017 results. Listeners may access the call by dialing:
US: 1 888 346 8982International: 1 412 902 4272 Hong Kong: 800 905 945 China: 400 120 1203
A telephone replay will be available one hour after the conclusion of the conference call through May 11, 2017. The dial-in details are:
US: 1 877 344 7529 International: 1 412 317 0088 Passcode: 10106035
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.
About China Biologic Products, Inc.
China Biologic is a leading plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd., and its wholly-owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals and inoculation centers, as well as distributors, in China. For additional information, please see the Company's website, www.chinabiologic.com.
China Biologic Products, Inc.Mr. Ming YinSenior Vice President Phone: +86-10-6598-3099Email: firstname.lastname@example.org
ICR Inc.Mr. Bill ZimaPhone: +86-10-6583-7511 or +1-646-405-5191E-mail: email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-biologic-products-to-report-first-quarter-of-2017-financial-results-300443363.html
SOURCE China Biologic Products, Inc.
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All